Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19
| Autor: | Sara Samir Mohamed Elmenshawy, Mohamed Farouk Ahmed Abdelsalam, Tarek Refaat El Nagdy, Mohamed Abdel Salam Elgohary, Nagwa Ali Sabri, Amal El-kholy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Future Science OA, Vol 10, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 20565623 2056-5623 |
| DOI: | 10.1080/20565623.2024.2418798 |
| Popis: | Aim: To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19.Materials & methods: A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period.Results: The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.Discussion: Different literature data indicate the superiority of TZV in treating COVID-19 when compared with other therapeutic agents. While there is controversy about the efficacy of oseltamivir.Conclusion: It was concluded that TZV is more effective than oseltamivir in the management of COVID-19 disease.Trial registration number: NCT04973462. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|